Dr. Kenneth Robert McGaffin, MD

Dr. McGaffin practices at AHN Premier Medical Associates One Monroeville Center in Monroeville, Pennsylvania.

Dr. McGaffin's NPI, 1750481800, was assigned on September 25, 2006. Dr. McGaffin graduated from Georgetown University School of Medicine in 1999. Dr. McGaffin holds Pennsylvania license MD419469.

Dr. McGaffin's primary practice is AHN Premier Medical Associates One Monroeville Center, at 3824 Northern Pike, Ste. 150, Monroeville, PA 15146. The practice phone is (412) 373-6342.

Dr. McGaffin's primary practice is AHN Premier Medical Associates One Monroeville Center in Monroeville, Pennsylvania. Dr. McGaffin is also affiliated with Forbes Hospital. The medical group on file is AHN Primary Care - Family Med Associates at H+W Pavilion Bethel Park. Dmand AI also links Dr. McGaffin to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account. Dr. McGaffin's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McGaffin practices, 8 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. McGaffin's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. McGaffin is licensed in Pennsylvania.

CMS data shows 2,810 Medicare services from Dr. McGaffin across 20 procedure codes in 2024, for 973 Medicare patients. Medicare paid $145,025 for them.

CMS counts 973 Medicare patients who saw Dr. McGaffin in 2024. The largest group is 65 to 74, with 477 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McGaffin's median patient age at 72, with 49% women.

In 2024, Dr. McGaffin wrote 6,179 Medicare Part D claims for 733 patients. 79% of them were for generic drugs. CMS names the drug for 5,797 of them, across 69 drugs with 11 or more claims each, at $1,255,618 in total drug cost. In 2023, CMS named 5,078 claims across 63 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. McGaffin for performance year 2024, reported through an alternative payment model (APM). Dr. McGaffin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. McGaffin, published from 2007 to 2012. 2012 was the busiest year, with 4. The most frequent topics are Signal Transduction, Myocardial Infarction and Heart Failure. Dr. McGaffin has published most often in Cardiovasc Res. Dr. McGaffin's most frequent co-authors are Laura Cristina Alonso, MD, Euhan John Lee, MD and Hilary Strollo, DO.

CMS Open Payments shows 215 general payments to Dr. McGaffin from 28 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 68% of the total. Sanofi and Genzyme US Companies paid the most, $973.

Dr. McGaffin graduated from Georgetown University School of Medicine in 1999.